Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Salmeterol Clear all
Terminated Phase 4 Interventional Results available

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

MGR001 / Advair Diskus Local Equivalence Study in Asthma

NCT02245672
View directory record Official record
Conditions
Asthma
Interventions
MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Mylan Pharma UK Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 84 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
12 Years and older
Enrollment
1,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

NCT02139644
View directory record Official record
Conditions
Asthma
Interventions
FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
76
States / cities
Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2021 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

The Effect on Depressive Symptoms in ECF Residents With COPD

NCT00974246
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Depression
Interventions
Advair diskus
Drug
Lead sponsor
Valley Medical Research
Other
Eligibility
18 Years to 94 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Brooksville, Florida • Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 3 Interventional

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

NCT00064402
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
Interventions
arformoterol tartrate inhalation solution, Salmeterol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
35 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
65
States / cities
Jasper, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 4 Interventional

Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

NCT00235053
View directory record Official record
Conditions
Asthma, Candidiasis, Oral, Voice Disorders
Interventions
fluticasone/salmeterol DISKUS 250/50
Drug
Lead sponsor
Allergy & Asthma Medical Group & Research Center
Other
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

NCT02433834
View directory record Official record
Conditions
Asthma
Interventions
Glycopyrronium MDI, Serevent Diskus 50 μg, Placebo
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Birmingham, Alabama • Anaheim, California • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 1 Interventional

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

NCT02680561
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate MDPI, Fluticasone Propionate/Salmeterol MDPI, Fluticasone propionate/salmeterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Huntington Beach, California • Raleigh, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

NCT00565266
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, salmeterol xinafoate, beclomethasone dipropionate
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 17, 2026, 4:15 AM EDT
Recruiting Phase 4 Interventional

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

NCT01225913
View directory record Official record
Conditions
Asthma
Interventions
fluticasone/salmeterol in all asthmatics, budesonide/formoterol or fluticasone/salmeterol in all asthmatics
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

NCT01772368
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, FS MDPI, Advair Diskus, Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 2 Interventional

Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

NCT00640484
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
carmoterol (CHF 4226), placebo, salmeterol
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01817764
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

NCT00452699
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
58
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 3 Interventional

A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.

NCT00274534
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Salmeterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
2
States / cities
Hines, Illinois • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

NCT00395304
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate + montelukast, fluticasone propionate, fluticasone propionate + salmeterol
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 18 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

NCT00118716
View directory record Official record
Conditions
Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions
Fluticasone propionate/salmeterol, Fluticasone Propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 17 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
50
States / cities
Little Rock, Arkansas • Huntington Beach, California • Orange, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

Long-acting Beta Agonist Step Down Study

NCT01437995
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone/Salmeterol Diskus, Fluticasone Diskus
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 17, 2026, 4:15 AM EDT
Withdrawn Not applicable Interventional

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

NCT00741767
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Sleep Disorders
Interventions
salmeterol-fluticasone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Best African American Response to Asthma Drugs

NCT01967173
View directory record Official record
Conditions
Asthma
Interventions
Flovent Diskus® 100 mcg, Flovent Diskus® 250 mcg, Flovent Diskus® 500 mcg, Advair Diskus® 100/50 mcg, Advair Diskus® 250/50 mcg
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years and older
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
28
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 17, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available

How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment

NCT00595361
View directory record Official record
Conditions
Asthma
Interventions
salmeterol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 17, 2026, 4:15 AM EDT
Recruiting No phase listed Observational

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

NCT00576069
View directory record Official record
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 17, 2026, 4:15 AM EDT